Resp Flashcards
Pulm fibrosis Ix
-Obs + ABG
- Bloods: fbc, U+E, lft, crp + ANA,ANCA,RF,antiCCP, dsDNA, Anti-Scl-70
-Sputum culture
-CXR (reticulonodular change) –> HRCT
-Pulmonary function test:
—> restrictive: FEV1/FVC >0.8
very reduced FVC,
Low transfer transfer factor
KCO low
Lower zone fibrosis
CTD - Lupus, RA, scleroderma
Asbestosis
Idiopathic - more likely clubbing - UIP
Drugs: MTX, amiodarone (AF), nitrofurantoin
Upper zone fibrosis
Hypersensitivity pneumonitis
Ank spond
Sarcoidosis
ABPA
Old TB
Langerhans cell histiocytosis
HRCT findings with pulmonary fibrosis
UIP = honeycombing - more often IPF
NSIP (non-specific) = ground glass - more often assoc CTD/AI disease
Treatment pul fibrosis
vaccine, smoking cessation, pul rehab,
treating course - CTD = immunosuppressive (steroids or steroid sparing)
if IPF - specialist centre to consider anti-fibrotic (pirfendidone ipf only)
Nintedanib can be used in other causes - strict criteria FEV1 50-80%
Single lung transplant
Prognosis of PF based on CT
GG changes - 80 % respond to immunosuppression
Honeycomb - 80% no response to immunosuppression
Pulmonary HTN causes
WHO clinical classification:
1) Pulmonary arterial hypertension - idiopathic
secondary: CTD, congenital heart disease, HIV, drugs/toxins
2) Left heart disease: function/valves
3) Lung disease: COPD, ILD, sarcoid
4) Chronic thromboembolic disease
5) Miscellaneous: long-term HD
Treatment for pulmonary hypertension
Based on cause:
1) PAH: pulmonary vasodilators - prostacyclin analogues, endothelin receptor antagonists, sildenaifl
4) lifelong anti coag
2,3,5) underlying cause
Investigation Pulm HTN
Fbc (anaemia), RFx, LFT (porto-pulmonary PH), HIV, autoimmune (SLE, scleroderma), TFT
Echo - RV size/function, estimate pulm pressure if TR, left sided disease re cause
Imaging: CTPA - if thromboembolic
Lung function tests - lung causes ILD/COPD
Dx: right heart catheterisation = raised pulmonary pressure
Complications pulm htn
R heart failure
Atrial arrhythmia
Risk of death in pregnancy (pulmonary blood flow increases significantly)